Karim Vermaelen
Overview
Explore the profile of Karim Vermaelen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2173
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Castro F, Pinto M, Leite Pereira C, Serre K, Costa A, Cavadas B, et al.
J Control Release
. 2025 Jan;
379:621-635.
PMID: 39832747
Interferon-γ (IFN-γ) is a key mediator in antitumor immunity and immunotherapy responses, yet its clinical applications remain restricted to chronic granulomatous disease and malignant osteopetrosis. IFN-γ effectiveness as a standalone...
2.
Martinez R, Finocchiaro C, Delhaye L, Gysens F, Anckaert J, Trypsteen W, et al.
Front Immunol
. 2024 Nov;
15:1444886.
PMID: 39497819
Cancer cells effectively evade immune surveillance, not only through the well-known PD-1/PD-L1 pathway but also alternative mechanisms that impair patient response to immune checkpoint inhibitors. We present a novel co-culture...
3.
Marcos Rubio A, Oh S, Roelandt S, Stevens D, Van Damme E, Vermaelen K, et al.
Sci Rep
. 2024 Oct;
14(1):26026.
PMID: 39472635
Transcriptomic profiling of blood immune cells offers a promising alternative to invasive, sampling bias-prone tissue-based biomarker assays for predicting immune checkpoint inhibitor (ICI) therapy response in non-small cell lung cancer...
4.
Hochmair M, Vermaelen K, Mountzios G, Carcereny E, Dooms C, Lee S, et al.
Eur J Cancer
. 2024 Jul;
208:114204.
PMID: 39029295
Background: Sotorasib 960 mg once daily is approved to treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Sotorasib exhibits non-dose proportional pharmacokinetics and clinical responses at...
5.
Ingels J, De Cock L, Stevens D, Mayer R, Thery F, Sanchez Sanchez G, et al.
Cell Rep Med
. 2024 Apr;
5(5):101516.
PMID: 38626769
Non-small cell lung cancer (NSCLC) is known for high relapse rates despite resection in early stages. Here, we present the results of a phase I clinical trial in which a...
6.
Marcos Rubio A, Everaert C, Van Damme E, De Preter K, Vermaelen K
J Immunother Cancer
. 2023 Aug;
11(8).
PMID: 37536935
The use of immune checkpoint inhibitors (ICIs) continues to transform the therapeutic landscape of non-small cell lung cancer (NSCLC), with these drugs now being evaluated at every stage of the...
7.
Ready N, Audigier-Valette C, Goldman J, Felip E, Ciuleanu T, Campelo M, et al.
J Immunother Cancer
. 2023 Feb;
11(2).
PMID: 36725084
Background: CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line...
8.
Van der Linden M, Van Gaever B, Raman L, Vermaelen K, Demedts I, Surmont V, et al.
Cancers (Basel)
. 2022 Apr;
14(8).
PMID: 35454937
Diagnosis of lung cancer requires histological examination of a tissue sample, which in turn requires an invasive procedure that cannot always be obtained. Circulating tumor DNA can be reliably detected...
9.
Van Acker L, Stevens D, Vermaelen K, Surmont V
J Med Case Rep
. 2021 Nov;
15(1):562.
PMID: 34809713
Background: The discovery of epidermal growth factor receptor oncogenic driver mutations has changed the therapeutic landscape of advanced non-small cell lung cancer in the past decade. Since the introduction of...
10.
Ingels J, De Cock L, Mayer R, Devreker P, Weening K, Heyns K, et al.
Cytotherapy
. 2021 Oct;
24(2):213-222.
PMID: 34696961
Messenger RNA (mRNA) has become a promising tool in therapeutic cancer vaccine strategies. Owing to its flexible design and rapid production, mRNA is an attractive antigen delivery format for cancer...